Abstract:HER2 extracellular domain (HER2_ECD) protein is a potential tumor vaccine for containing more antigenic epitopes that have more potent immunogenicity than the antigenic polypeptide. Transmembrane and secretory antigens are different in receptor binding, biological effects and action mechanisms. Therefore, it is necessary to prepare two kinds of HER2_ECD protein for its potential application. In this study, pDisplay and pCMV were used as vectors for the expression of transmembrane and secretory HER2_ECD. A sequence of transmembrane region (PDGFR Transmembrane Domain) is located behind the signal peptide and the cleavage site in the pDisplay. The PCR product HER2_ECD fragment was cloned into pDisplay to form recombinant plasmid pDisplay-HER2_ECD which was then transiently transfected in HEK293T cells. The expressed protein was confirmed to be 130kDa by Western Blotting, which was in agreement with the theoretical size of HER2_ECD. The positive rate of the transient cells in the experimental group was from 51.00% to 52.08% compared with the blank control group by flow fluorescence analysis. Moreover, green fluorescence (FITC) and red fluorescence (PE) were observed on the parallel cells of the experimental group compared with the blank control group by confocal microscopy fluorescence detection, which indicated that HER2_ECD was successfully expressed on the membrane. In order to facilitate the expression, purification and test, an Fc fragment was fused with HER2_ECD by overlap PCR then cloned into pCMV to get the recombinant plasmid pCMV-HER2_ECD-Fc which was then transiently transfected in HEK293T cells. Western Blotting analysis suggested that the expressed protein collected from the supernatant was 150 kDa, which was in accordance with the theoretical size of HER2_ECDFc. Purified by protein an affinity chromatography, the purity of recombinant HER2_ECD-Fc was confirmed to be 98.10% by SDS-PAGE and HPLC. In summary, transmembrane and secretory HER2_ECD proteins were successful prepared to be homogenesis by membranedocking and secretory expression in mammalian cells.

Construction and Biological Function of Eukaryotic Expression Vector for Myctagged HER2

Construction and Identification of Lentiviral Vector-mediated RNA Interference of Epidermal Growth Factor Receptor

Construction of Human H-ras Eukaryotic Expression Vector and its Proliferative Role in Cancer Cell Growth

Construction of myc- Tagged Human Six1 Eukaryotic Expression Vector and its Activity Detection

Construction of myc-Tagged Human EYA3 Eukaryotic Expression Vector and its Activity Detection

Construction of Human VHL Eukaryotic Expression Vector and its Suppressive Role in Cancer Cell Growth

Construction and the Immune Reactivity of the Anti-cancer Vaccine of Recombinant Bacteriophage T7 Targeting Epidermical Growth Factor Receptor

Construction of myc-Tagged Human Bcl2 Eukaryotic Expression Vector and its Anti-Apoptotic Activity Detection

Construction of Flag-Tagged Human NKX2-3 Eukaryotic Expres-sion Vector and its Role on Tumor Cell Growth

Construction of V-Myc Expression Vector

[Construction and Expression of Bisbicistronic Expression Vector of Novel Endocrine and Exocrine Protein Gene Associated with Breast Cancer and IRES Mediated Gene EGFP].

Expression and identification of transmembrane and secretory human HER 2 extracellular domain

Construction and Expression of hST3Gal Ⅰ Eukaryotic Expression Vector in Human Breast Carcinoma Cells

Construction of Human K-ras Eukaryotic Expression Vector and its Biological Function Research

Construction and identification of plasmid vector of CDK7

[Vector-Mediated HER-2 RNA Interference Against HER-2-positive Breast Cancer].

Eukaryotic Expression Vectors Construction and Transcriptional Ac tivity Analysis of Different Isoforms of ERβ in Breast Cancer

Construction and Identification of Eukaryotic Expression Vector of MAGE-3-HSP70 Fusion Gene

Construction of pEGFP-C1-CXCL1 plasmid and detection of its expression in eukaryotic cells

Cloning and Prokaryotic Expression of HER-2/neu Extracellular Domain

Construction of multidrug resistance hepatocellular carcinoma cell model